Shandong New Time Pharmaceutical Co., Ltd
Clinical trials sponsored by Shandong New Time Pharmaceutical Co., Ltd, explained in plain language.
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launched
Disease control Recruiting nowThis study tests a new drug called F182112 against standard treatments in 261 adults with multiple myeloma that has returned or stopped responding to prior therapies. The goal is to see if the new drug can delay cancer growth longer than usual care. Participants must have already…
Phase: PHASE3 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for hard-to-treat myeloma: experimental combo tested in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called F182112 given with different treatment plans for people whose multiple myeloma has returned or stopped responding to prior therapies. About 90 participants will receive the drug combination to see if it shrinks tumors and how safe it is. The goa…
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC